MAPT and non-small cell lung carcinoma: Accordingly, the present prospective, randomized, non-interventional study was performed to verify the predictive value of BRCA1, TUBB3, MAPT and STMN1 in patients with NSCLC that received adjuvant platinum-based chemotherapy.